Literature DB >> 23252354

The changing role of economic evaluation in valuing medical technologies.

Jason S Rotter1, Douglas Foerster, John Fp Bridges.   

Abstract

Economic evaluation is established within health-technology assessment but is challenged by those wanting to use economic evaluation to inform pricing and/or incorporate nontraditional sources of value and the views of diverse stakeholders. The changing role of economic evaluation in (formally or informally) assessing prices/values in four jurisdictions (UK, Australia, Germany and USA) is detailed and the authors propose a taxonomy of factors impacting the value of medical technology spanning clinical utility (effectiveness, safety/tolerability and quality of evidence), consumer demand (consumer preferences, process utility and unmet need), economic incentives (innovation, option value and market competition) and the societal perspective (social justice, social values and national interest). The authors suggest that multicriteria decision analysis methods grounded in hedonic-pricing theory can facilitate the valuing/pricing of medical technologies. The use of such an approach is hindered by a paucity of relevant educational opportunities, vested interests and aversion to placing prices/values on health.

Mesh:

Year:  2012        PMID: 23252354     DOI: 10.1586/erp.12.73

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  8 in total

Review 1.  Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review.

Authors:  Vadim Dukhanin; Alexandra Searle; Alice Zwerling; David W Dowdy; Holly A Taylor; Maria W Merritt
Journal:  Soc Sci Med       Date:  2017-12-14       Impact factor: 4.634

2.  Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.

Authors:  Susanne Schmitz; Laura McCullagh; Roisin Adams; Michael Barry; Cathal Walsh
Journal:  Pharmacoeconomics       Date:  2016-09       Impact factor: 4.981

Review 3.  The Value of Medicines: A Crucial but Vague Concept.

Authors:  Fernando Antoñanzas; Robert Terkola; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

4.  Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.

Authors:  Peter Ghijben; Yuanyuan Gu; Emily Lancsar; Silva Zavarsek
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

5.  Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

Authors:  Axel C Mühlbacher; John F P Bridges; Susanne Bethge; Ch-Markos Dintsios; Anja Schwalm; Andreas Gerber-Grote; Matthias Nübling
Journal:  Eur J Health Econ       Date:  2016-02-04

6.  Stakeholder opinions on value in healthcare.

Authors:  Robert Terkola; Fernando Antoñanzas; Maarten Postma
Journal:  Eur J Hosp Pharm       Date:  2017-10-25

7.  Methods of international health technology assessment agencies for economic evaluations--a comparative analysis.

Authors:  Tim Mathes; Esther Jacobs; Jana-Carina Morfeld; Dawid Pieper
Journal:  BMC Health Serv Res       Date:  2013-09-30       Impact factor: 2.655

8.  Using multicriteria decision analysis during drug development to predict reimbursement decisions.

Authors:  Paul Williams; Josephine Mauskopf; Jake Lebiecki; Anne Kilburg
Journal:  J Mark Access Health Policy       Date:  2014-10-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.